Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

August 7, 2014

Webcast: Conference Call August 7, 2014 4:00 PM EDT

Provectus management will host a conference call Thursday August 7, 2014 at 4:00 PM EDT.

August 4, 2014

Intralesional PV-10

Dr. Sanjiv Agarwala, Professor of Medicine, St. Luke's Cancer Center and Temple University, gave a presentation entitled "Intralesional PV-10" at the 10th European Association of Dermato Oncology (EADO) Congress in Vilnius, Lithuania.

July 29, 2014

Topical and intralesional immunotherapy for melanoma metastases

A DermNet New Zealand Trust article discusses investigational melanoma drugs, including PV-10, that are being used to deliver therapy directly into a local recurrence or metastasis with the goal of destroying the target lesion and stimulating regression of other, untreated lesions by inducing an immune response to the melanoma.

July 29, 2014

Intralesional Injections Trigger Immune Responses in Melanoma

An article published in Volume 5, Issue 12 of The ASCO Post discusses the emerging approach to treating metastatic melanoma by stimulating an immune response using intralesional injections of investigational melanoma drugs, including PV-10.

July 29, 2014

Update: Response to Class Action Lawsuit

On May 29, 2014 we posted a notice that a class action lawsuit styled Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated, v. Provectus Biopharmaceuticals, Inc., H. Craig Dees, Timothy C. Scott, and Peter R. Culpepper had been filed alleging violations of United States federal securities laws and that we dispute the allegations in the complaint and intend to defend this lawsuit. Our position on this lawsuit has not changed. We continue to dispute the allegations and intend to vigorously defend this lawsuit.

July 18, 2014

Reports from the 50th American Society of Clinical Oncology (ASCO) Annual Meeting

An article appearing in the July/August 2014 issue of Oncology News reports that data presented at ASCO underline the way immunotherapy is reshaping the treatment of melanoma, not just in metastatic melanoma, but also in locally advanced cutaneous melanoma with PV-10.

June 19, 2014

Webcast: Conference Call June 19, 2014 4:00 PM EDT

Provectus management will host a conference call Thursday June 19, 2014 at 4:00 PM Eastern.

June 19, 2014

PV-10: study shows 50% of cutaneous melanoma patients achieve complete response

An article appearing in Pharmiweb reports on Phase 2 PV-10 data recently presented at the 50th American Society of Clinical Oncology meeting (ASCO)).

June 10, 2014

Provectus outlines path forward for PV-10

An article appearing in ecancer news entitled "Provectus outlines path forward for PV-10" reports on Provectus' announced plan to initiate a Phase 3 randomised controlled trial where 210 patients with unresectable locally advanced cutaneous melanoma will be randomised 2:1 to PV-10 or systemic chemotherapy.

June 10, 2014

PV-10 produced complete response in 50% of advanced melanoma patients

An article appearing in Medical News Today entitled "PV-10 produced complete response in 50% of advanced melanoma patients" reports on Phase 2 PV-10 data recently presented at the 50th American Society of Clinical Oncology meeting (ASCO)).

June 3, 2014

Webcast: Conference Call June 3, 2014 8:30 AM EDT

Provectus management will host a conference call Tuesday June 3, 2014 at 8:30 AM Eastern.

May 29, 2014

Response to Class Action Lawsuit

A class action lawsuit styled Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated, v. Provectus Biopharmaceuticals, Inc., H. Craig Dees, Timothy C. Scott, and Peter R. Culpepper has been filed against Provectus and certain officers of Provectus alleging violations of United States federal securities laws. We dispute the allegations in the complaint and intend to vigorously defend this lawsuit.

May 29, 2014

Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Market

The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus is still committed to bringing the investigational melanoma therapy to market.

May 23, 2014

Webcast: Conference Call May 23, 2014 4PM

Provectus management will host a conference call Friday May 23, 2014 at 4 PM Eastern.

May 21, 2014

PV-10 data for break through therapy designation application highlighted by ASCO

An article appearing in eCancer News reports on a subgroup analysis of PV-10 Phase 2 data that provides the basis for the pending breakthrough therapy designation application for PV-10 submitted to the FDA in March 2014.

May 9, 2014

Dr. Sanjiv Agarwala Discusses PV-10 on Daybreak USA

USA Radio National's Daybreak USA recently interviewed Dr. Sanjiv Agarwala in recognition of melanoma awareness month.

May 8, 2014

European Association of Dermato-Oncology Congress Presentation Slides Now Available

Slides from Dr. Sanjiv S. Agarwala's presentation at the 10th European Association of Dermato-Oncology Congress in Vilnius, Lithuania are now available.

April 30, 2014

New Melanoma Therapies Are Ready for Primetime: Sanjiv Agarwala

In an interview appearing April 29, 2014 in The Life Sciences Report, Dr. Sanjiv Agarwala discusses melanoma and new melanoma therapies.

April 29, 2014

PV-10 Treatment Decreases Melanoma Cells in Tumors

An article appearing in the April 2014 edition of Cancer Watch reports on data presented by Moffitt Cancer Center researchers demonstrating significant decreases in melanoma cells in injected tumors and uninjected bystander tumors.

April 9, 2014

Investigational drug PV-10 decreases melanoma cells in tumors

An April 8, 2014 article in Dermatology Times reports on PV-10 study findings recently presented by Moffitt Cancer Center researchers at the 2014 AARC annual meeting.

more...

PRESS RELEASES

August 18, 2014

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it entered into a Memorandum of Understanding ("MOU") with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

August 6, 2014

Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will begin a series of regular quarterly conference calls to update the market in general and shareholders in particular about developments at the Company. In the future, these calls will coincide with the filing of the Company's 10-Q and 10-K filings with the Securities and Exchange Commission as appropriate.

July 23, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will have clinical data on PV-10 presented at the European Society for Medical Oncology's 2014 Congress in Madrid, Spain.

July 8, 2014

Provectus Updates Shareholders in Its Annual CEO Letter

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2013, and shares as well as insights on upcoming plans and milestones for 2014.

June 19, 2014

Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.

June 12, 2014

Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

June 3, 2014

PV-10 Data Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Defines Path Forward for Provectus Biopharmaceuticals, Inc.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

May 27, 2014

Provectus Biopharmaceuticals Inc. to Hold Conference Call Tuesday, June 3, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Tuesday, June 3, 2014 at 8:30 a.m. EDT.

May 23, 2014

Provectus Biopharmaceuticals Inc. Reaffirms Its Commitment to Bringing PV-10 to Market Notwithstanding FDA Decision on Breakthrough Therapy Designation

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received notification from the United States Food and Drug Administration that the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies. As a result, the FDA has declined to designate PV-10 as a Breakthrough Therapy at this time. Further data may cause the Agency to revisit this decision at a later date. PV-10 is the Company's novel investigational drug for solid tumors.

May 21, 2014

Provectus Biopharmaceuticals, Inc. Refutes Inaccuracies in Seeking Alpha Article

KNOXVILLE, Tenn.--(BUSINESS WIRE)--It has come to the attention of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com) that an article was published on seekingalpha.com on May 21, 2104, which contains numerous inaccuracies and misstatements about the Company.

May 21, 2014

Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (PVCT)www.pvct.com), announced today that it has appointed Jacob M. Plotsker to its strategic advisory board.

May 19, 2014

Provectus Biopharmaceuticals to Celebrate NYSE MKT Listing with Opening Bell Ceremony

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (PVCT)www.pvct.com), announced today that its CEO and Chairman Dr. Craig Dees, PhD, its CTO Dr. Eric Wachter, PhD and its CFO and COO Peter Culpepper, along with Alfred E. Smith, IV, Lead Independent Director of its Board, along with key advisors will ring The Opening Bell® at the New York Stock Exchange at 9:30 a.m. EDT on Thursday, May 22, 2014.

May 16, 2014

Provectus Biopharmaceuticals Inc.'s Common Shares to Begin Trading on NYSE MKT

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced that its shares will begin trading on the NYSE MKT today Friday May 16, 2014.

May 15, 2014

Provectus Biopharmaceuticals' PV-10 Data Show Exceptional Complete Response Rates in Refractory Melanoma Patients

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma will be featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago, IL.

May 14, 2014

Provectus Biopharmaceuticals' PV-10 Data Show Exceptional Complete Response Rates in Refractory Melanoma Patients

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma will be featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago, IL.

May 13, 2014

Provectus Biopharmaceuticals Inc. to List on NYSE MKT

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that its shares of common stock have been approved for listing on the NYSE MKT. Shares will begin trading on the NYSE MKT on Friday May 16, 2014.

May 6, 2014

Provectus Biopharmaceuticals Inc. Appoints Brendan O'Brien to Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has appointed Brendan O'Brien to its strategic advisory board.

April 28, 2014

Provectus Biopharmaceuticals Inc. Retains Roberti+White, LLC as Public Policy Consultants

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has retained the services of Roberti+White, LLC as its public policy consultants.

April 21, 2014

Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania.

April 14, 2014

Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing.

more...